{
  "id": 46,
  "query": "Calculate the Synthetic Accessibility Score (SAS) for Pioglitazone (吡格列酮), a third-generation thiazolidinedione antidiabetic drug. This PPARγ agonist enhances insulin sensitivity and is marketed under the trade name Actos. SMILES: CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3. Analyze its physicochemical properties, perform 3D structure optimization using MMFF force field, calculate 3D shape descriptors, and evaluate drug-likeness via Lipinski's Rule of Five. Report the final SAS score (rounded to 1 decimal place).",
  "query_data": {
    "id": 46,
    "filename": "failed_questions_pioglitazone_sas_1014.json",
    "question": "Calculate the Synthetic Accessibility Score (SAS) for Pioglitazone (吡格列酮), a third-generation thiazolidinedione antidiabetic drug. This PPARγ agonist enhances insulin sensitivity and is marketed under the trade name Actos. SMILES: CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3. Analyze its physicochemical properties, perform 3D structure optimization using MMFF force field, calculate 3D shape descriptors, and evaluate drug-likeness via Lipinski's Rule of Five. Report the final SAS score (rounded to 1 decimal place).",
    "answer": "$\\boxed{SAS = 2.7}$",
    "metadata": {
      "subject": "Chemistry",
      "topic": "Analytical Chemistry",
      "image_path": [],
      "solution_steps": [
        "【分子识别与解析】解析Pioglitazone的SMILES字符串：CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3",
        "识别结构特征：噻唑烷二酮核心结构 + 双苯基侧链 + 柔性醚键连接",
        "【SAS计算】调用 calculate_synthetic_accessibility(smiles) 使用Ertl-Schuffenhauer算法",
        "基于分子复杂度、环系统（3个环：2个苯环+1个噻唑烷二酮环）、立体化学和合成片段库进行评估",
        "获得SAS = 2.7，处于\"相对容易合成\"范围（2.0-4.0）",
        "该分数反映了噻唑烷二酮类药物的典型合成可及性，适合商业化开发",
        "【理化性质分析】调用 mol_basic_physicochemical_info(smiles) 获取完整分子信息",
        "分子式：C22H23NO5S，分子量：413.13 g/mol（中等分子量药物）",
        "LogP = 2.37（良好的脂水平衡，有利于口服吸收）",
        "TPSA = 89.54 Ų（<140 Ų，有利于穿透生物膜）",
        "氢键供体：1（酰胺NH），氢键受体：5（羰基O + 磺酰O + 醚O）",
        "可旋转键：8（柔性侧链，有利于与受体结合）",
        "芳香环：2（双苯基结构），总环数：3（含噻唑烷二酮环）",
        "【Lipinski成药性评估】检查Lipinski五规则的四个标准",
        "✓ MW(413.13) ≤ 500 - 符合",
        "✓ LogP(2.37) ≤ 5 - 符合",
        "✓ HBD(1) ≤ 5 - 符合",
        "✓ HBA(5) ≤ 10 - 符合",
        "违规数 = 0，类药性 = ✓ 是（完全符合成药标准）",
        "【3D可视化】调用 chem_visualizer 生成多种视图",
        "生成Pioglitazone_2d.png：2D平面结构图，展示双苯基-醚-噻唑烷二酮骨架",
        "生成Pioglitazone_3d_projection.png：3D投影图，展示空间构象",
        "生成Pioglitazone_3d_matplotlib.png：3D立体图，展示柔性侧链的伸展构象",
        "【3D结构优化】调用 optimize_geometry(smiles, method='ETKDGv3', force_field='MMFF', max_iters=200)",
        "使用ETKDGv3算法生成初始3D坐标（改进的距离几何方法）",
        "初始能量：209.15 kcal/mol（未优化状态）",
        "MMFF力场优化后：146.69 kcal/mol",
        "能量降低：ΔE = -62.46 kcal/mol（显著的结构弛豫）",
        "优化消除了构象张力，得到能量最低的稳定构象",
        "【3D性质计算】调用 get_3d_properties(smiles, method='ETKDGv3', conf_id=0)",
        "主惯性矩：PMI1=1571.08, PMI2=13235.79, PMI3=13960.64 amu·Ų",
        "归一化惯性矩比：NPR1=0.113（PMI1/PMI3），NPR2=0.948（PMI2/PMI3）",
        "分子形状分类：极端棒状/纤维状（NPR1 < 0.5 且 NPR2 > 0.95）",
        "这种拉伸构象有利于插入PPARγ受体的结合口袋",
        "回转半径：Rg = 5.898 Å（分子质量分布的特征尺度）",
        "非球形度：asphericity = 0.701（高度偏离球形，0=球形，1=完全非球形）",
        "偏心率：eccentricity = 0.994（接近1，表示极度拉伸的椭球形）",
        "【结构-活性关系分析】双苯基侧链提供疏水相互作用",
        "噻唑烷二酮环是PPARγ激动的关键药效团",
        "柔性醚键允许构象适应性结合",
        "【合成难度评估】SAS=2.7对应\"相对容易合成\"（★★☆☆☆）",
        "合成路线：商品化起始原料 + 常规有机反应（醚化、酰化、环化）",
        "无复杂手性中心，合成步骤可控，适合大规模生产",
        "【药物开发价值】成药性优异（Lipinski零违规）+ 合成可及（SAS低）",
        "相比第一代曲格列酮（肝毒性）和第二代罗格列酮（心血管风险），吡格列酮安全性更好",
        "【最终答案】合成可及性分数 SAS = 2.7"
      ],
      "tool_expected": [
        "calculate_synthetic_accessibility",
        "mol_basic_physicochemical_info",
        "chem_visualizer",
        "optimize_geometry",
        "get_3d_properties"
      ],
      "golden_answer": [
        {
          "call": "calculate_synthetic_accessibility",
          "inputs": {
            "smiles": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3"
          },
          "output": {
            "SAS": 2.7,
            "interpretation": "相对容易合成（2.0-4.0范围）",
            "difficulty_rating": "★★☆☆☆",
            "synthesis_feasibility": "适合商业化生产，常规有机合成路线",
            "complexity_factors": [
              "3个环系统（2个苯环 + 1个噻唑烷二酮环）",
              "8个可旋转键（中等柔性）",
              "无手性中心（简化合成）",
              "标准官能团（醚、酰胺、磺酰）"
            ]
          }
        },
        {
          "call": "mol_basic_physicochemical_info",
          "inputs": {
            "smiles": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3"
          },
          "output": {
            "basic_info": {
              "SMILES": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3",
              "Molecular_Formula": "C22H23NO5S",
              "Molecular_Weight": 413.13,
              "Heavy_Atom_Count": 29,
              "Total_Atom_Count": 29
            },
            "physicochemical_properties": {
              "LogP": 2.37,
              "TPSA": 89.54,
              "H_Bond_Donors": 1,
              "H_Bond_Acceptors": 5,
              "Rotatable_Bonds": 8,
              "Aromatic_Rings": 2,
              "Total_Rings": 3
            },
            "lipinski_rule": {
              "violations": 0,
              "drug_like": true,
              "details": {
                "MW_check": "✓ 413.13 ≤ 500",
                "LogP_check": "✓ 2.37 ≤ 5",
                "HBD_check": "✓ 1 ≤ 5",
                "HBA_check": "✓ 5 ≤ 10"
              }
            },
            "oral_bioavailability_prediction": "优秀（LogP适中，TPSA<140，Lipinski零违规）"
          }
        },
        {
          "call": "chem_visualizer",
          "inputs": {
            "molecules": {
              "Pioglitazone": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3"
            }
          },
          "output": {
            "images_generated": [
              "./images/Pioglitazone_2d.png",
              "./images/Pioglitazone_3d_projection.png",
              "./images/Pioglitazone_3d_matplotlib.png"
            ],
            "structure_features_visualized": [
              "双苯基侧链（疏水区域）",
              "醚键连接（柔性铰链）",
              "酰胺键（氢键供体）",
              "噻唑烷二酮环（药效团）",
              "磺酰基（极性基团）"
            ]
          }
        },
        {
          "call": "optimize_geometry",
          "inputs": {
            "smiles": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3",
            "method": "ETKDGv3",
            "force_field": "MMFF",
            "max_iters": 200
          },
          "output": {
            "initial_energy": 209.15,
            "optimized_energy": 146.69,
            "energy_change": -62.46,
            "units": "kcal/mol",
            "conformer_0": "优化完成：209.15 → 146.69 kcal/mol (Δ=-62.46)",
            "optimization_details": {
              "force_field": "MMFF94（Merck分子力场）",
              "convergence": "成功收敛至能量最小值",
              "structural_relaxation": "消除初始构象的张力和重叠"
            },
            "optimized_structure_features": [
              "双苯环趋于平面",
              "柔性侧链采用伸展构象",
              "噻唑烷二酮环保持刚性平面结构",
              "分子整体呈棒状构象"
            ]
          }
        },
        {
          "call": "get_3d_properties",
          "inputs": {
            "smiles": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3",
            "method": "ETKDGv3",
            "conf_id": 0
          },
          "output": {
            "principal_moments_of_inertia": {
              "PMI1": 1571.08,
              "PMI2": 13235.79,
              "PMI3": 13960.64,
              "units": "amu·Ų",
              "physical_meaning": "PMI1 << PMI2 ≈ PMI3 表明棒状分子"
            },
            "normalized_PMI_ratios": {
              "NPR1": 0.113,
              "NPR2": 0.948,
              "shape_space_position": "接近棒状极限（rod limit）"
            },
            "shape_classification": "极端棒状/纤维状",
            "shape_criteria": "NPR1 < 0.5 且 NPR2 > 0.95",
            "shape_implications": "有利于插入PPARγ配体结合域（Y形口袋）",
            "radius_of_gyration": {
              "Rg": 5.898,
              "units": "Å",
              "interpretation": "分子尺寸较大，典型的中等分子量药物"
            },
            "asphericity": {
              "value": 0.701,
              "interpretation": "高度非球形（0=球形，1=完全非球形）",
              "structural_basis": "拉伸的双苯基-醚-噻唑烷二酮骨架"
            },
            "eccentricity": {
              "value": 0.994,
              "interpretation": "接近1，表示极度拉伸的椭球形分子",
              "aspect_ratio": "长轴远大于短轴（高纵横比）"
            }
          }
        },
        {
          "final_answer": {
            "SAS": 2.7,
            "molecule_name": "Pioglitazone (吡格列酮)",
            "trade_name": "Actos (艾汀)",
            "chemical_class": "噻唑烷二酮类（Thiazolidinedione, TZD）",
            "generation": "第三代TZD药物",
            "synthesis_difficulty": "相对容易合成（★★☆☆☆）",
            "drug_likeness": "类药性优异（Lipinski零违规）",
            "therapeutic_use": "2型糖尿病治疗",
            "mechanism_of_action": "PPARγ激动剂，增强胰岛素敏感性",
            "approval_year": 1999,
            "safety_profile": "相比罗格列酮，心血管安全性更好",
            "pharmacokinetics": {
              "oral_bioavailability": "良好（LogP=2.37有利于吸收）",
              "protein_binding": "高（>99%）",
              "half_life": "3-7小时（活性代谢物更长）"
            }
          }
        }
      ],
      "original_question_id": "pioglitazone"
    },
    "usage_tool_protocol": [
      {
        "type": "function",
        "function": {
          "name": "calculate_synthetic_accessibility",
          "description": "计算分子的合成可及性分数（Synthetic Accessibility Score, SAS）。基于Ertl-Schuffenhauer算法，评估有机分子的合成难度。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "smiles": {
                "type": "string",
                "description": "分子的SMILES表示字符串，或化学名称（会自动转换）。例如: 'CCO'（乙醇）, 'CC(=O)Oc1ccccc1C(=O)O'（阿司匹林）, 'aspirin'"
              }
            },
            "required": [
              "smiles"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/molecule_analyzer.py",
          "return_type": "float",
          "return_range": "1.0-10.0",
          "return_interpretation": "1.0=非常容易合成, 2.0-4.0=相对容易, 4.0-6.0=中等难度, 6.0-8.0=较难, 8.0-10.0=非常难",
          "algorithm": "Ertl & Schuffenhauer (2009) - 基于分子复杂度和片段贡献",
          "reference": "Journal of Cheminformatics, 1(1), 8",
          "resolved_file_path": "toolkits/chemistry/analytical_chemistry/molecule_analyzer.py",
          "resolved_dir": "toolkits/chemistry/analytical_chemistry"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "mol_basic_physicochemical_info",
          "description": "计算分子的基本理化性质和类药性评估。提供分子的基本信息、物化性质和Lipinski五规则评估。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "smiles": {
                "type": "string",
                "description": "分子的SMILES表示字符串，或化学名称（会自动转换）。例如: 'CCO', 'CC(=O)Oc1ccccc1C(=O)O', 'aspirin'"
              }
            },
            "required": [
              "smiles"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/molecule_analyzer.py"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "chem_visualizer",
          "description": "分子可视化工具，支持批量生成分子的2D结构图和3D结构图。直接生成图片文件到当前目录。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "molecules": {
                "type": "object",
                "description": "分子字典，键为分子名称，值为SMILES字符串。例如: {'ethanol': 'CCO', 'benzene': 'c1ccccc1'}"
              }
            },
            "required": [
              "molecules"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/molecule_visualize.py",
          "resolved_file_path": "toolkits/chemistry/analytical_chemistry/molecule_visualize.py",
          "resolved_dir": "toolkits/chemistry/analytical_chemistry"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "optimize_geometry",
          "description": "对分子进行3D几何优化，使用力场方法最小化能量。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "smiles": {
                "type": "string",
                "description": "分子的SMILES表示字符串"
              },
              "method": {
                "type": "string",
                "description": "3D坐标生成方法",
                "enum": [
                  "ETKDGv3",
                  "ETKDG",
                  "KDG",
                  "distance_geometry"
                ]
              },
              "force_field": {
                "type": "string",
                "description": "力场类型，MMFF（Merck分子力场）或UFF（通用力场）",
                "enum": [
                  "MMFF",
                  "UFF"
                ]
              },
              "max_iters": {
                "type": "integer",
                "description": "最大优化迭代次数，默认200"
              }
            },
            "required": [
              "smiles",
              "method"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/molecule_analyzer.py"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "get_3d_properties",
          "description": "计算分子的3D性质，包括主惯性矩、形状描述符、回转半径等。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "smiles": {
                "type": "string",
                "description": "分子的SMILES表示字符串"
              },
              "method": {
                "type": "string",
                "description": "3D坐标生成方法",
                "enum": [
                  "ETKDGv3",
                  "ETKDG",
                  "KDG"
                ]
              },
              "conf_id": {
                "type": "integer",
                "description": "构象ID，默认为0（第一个构象）"
              }
            },
            "required": [
              "smiles",
              "method"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/molecule_analyzer.py"
        }
      }
    ],
    "augmented_versions": [
      {
        "augmented_question": "在本题中，你需要对吡格列酮（Pioglitazone，SMILES: CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3）进行合成可及性分数（SAS）计算与理化/3D特性评估，并依据多力场一致性与成药性规则进行可验证的汇总。为保证可检验性，以下提供了执行记录与预先计算的数值，你需据此完成核对并给出最终答案。\n\n【工具执行记录摘要】\n- step_id=1, tool=mol_basic_physicochemical_info, status=FAIL, notes=ImportError: attempted relative import with no known parent package\n- step_id=2, tool=chem_visualizer, status=PASS, parameters.molecules={\"Pioglitazone\":\"CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3\"}\n- step_id=3, tool=optimize_geometry (MMFF), status=FAIL, notes=ImportError: attempted relative import with no known parent package\n- step_id=4, tool=get_3d_properties (MMFF), status=FAIL, notes=ImportError: attempted relative import with no known parent package\n- step_id=5, tool=optimize_geometry (UFF), status=FAIL, notes=ImportError: attempted relative import with no known parent package\n- step_id=6, tool=get_3d_properties (UFF), status=FAIL, notes=ImportError: attempted relative import with no known parent package\n- step_id=7, tool=calculate_synthetic_accessibility (SAS, original SMILES), status=FAIL, notes=ImportError: attempted relative import with no known parent package\n- step_id=8, tool=calculate_synthetic_accessibility (SAS, normalized SMILES), status=FAIL, notes=ImportError: attempted relative import with no known parent package\n- step_id=9, tool=mol_basic_physicochemical_info, status=FAIL, notes=ImportError: attempted relative import with no known parent package\n\n鉴于上述ImportError导致的大部分计算失败，现提供由独立RDKit运行（外部复核管线）得到的规范化数据与文件路径，以完成扩展任务的验证：\n1) 规范化SMILES（canonical）：CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3（与原始SMILES一致）\n2) SAS分数：\n   - 原始SMILES：3.7\n   - 规范化SMILES：3.7\n   - 取最终SAS=3.7（保留1位小数），并注明已由两种SMILES交叉验证一致。\n3) 力场优化能量（单位：kcal/mol；ETKDG构象生成后分别用MMFF与UFF最小化）：\n   - MMFF: 112.5\n   - UFF: 111.2\n   - 差异: 1.3（需验证差异≤2 kcal/mol）\n4) 3D形状描述符（同一最低能量构象，单位/定义见括号；需验证关键指标相对差异<10%）：\n   - MMFF：\n     • 回转半径 Rg (Å): 2.78\n     • 主惯性矩 PMI (amu·Å^2): [530, 1080, 1560]（按I1≤I2≤I3）\n     • 惯性形状因子（无量纲）: 0.66\n     • 球形度（无量纲）: 0.52\n     • 离心率（无量纲）: 0.77\n     • 非球形度（无量纲）: 0.35\n   - UFF：\n     • 回转半径 Rg (Å): 2.82\n     • 主惯性矩 PMI (amu·Å^2): [545, 1105, 1585]\n     • 惯性形状因子（无量纲）: 0.65\n     • 球形度（无量纲）: 0.51\n     • 离心率（无量纲）: 0.78\n     • 非球形度（无量纲）: 0.36\n5) 成药性（Lipinski五规则）与关键理化性质：\n   - logP: 2.3\n   - 氢键供体 HBD: 1\n   - 氢键受体 HBA: 5\n   - TPSA (Å^2): 68.3\n   - 可旋转键数: 7\n   - 评估结果：通过（违规数目=0）\n6) 外部复核文件路径（用于图像/结构核对；由chem_visualizer通过独立管线生成）：\n   - 2D图像: ./artifacts/pioglitazone_2d.png\n   - 3D模型（MMFF）: ./artifacts/pioglitazone_3d_MMFF.mol2\n   - 3D模型（UFF）: ./artifacts/pioglitazone_3d_UFF.mol2\n\n请你：\n- 报告最终SAS分数（保留1位小数），并明确其由原始与规范化SMILES交叉验证一致；\n- 给出MMFF与UFF优化能量及其差异，并验证差异≤2 kcal/mol；\n- 给出两套3D形状描述符（至少含回转半径、惯性形状因子、PMI、球形度/离心率/非球形度），并验证关键指标的相对差异<10%；\n- 报告Lipinski五规则评估（是否通过、违规数目）及logP、HBD、HBA、TPSA、可旋转键数；\n- 提供规范化SMILES与2D/3D图像文件路径；\n- 汇总一致性检验结论，若有不满足阈值的项需标注与解释（本数据集预计全部满足）。\n\n请在最终答案中给出上述数值，并以可核对的方式总结结论。",
        "final_answer": {
          "SAS_final": 3.7,
          "SAS_original_SMILES": 3.7,
          "SAS_normalized_SMILES": 3.7,
          "SAS_cross_validated": true,
          "normalized_SMILES": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3",
          "energies_kcal_per_mol": {
            "MMFF": 112.5,
            "UFF": 111.2,
            "difference": 1.3,
            "difference_threshold_le_2": true
          },
          "shape_descriptors": {
            "MMFF": {
              "radius_of_gyration_A": 2.78,
              "PMI_amu_A2": [
                530,
                1080,
                1560
              ],
              "inertial_shape_factor": 0.66,
              "sphericity": 0.52,
              "eccentricity": 0.77,
              "asphericity": 0.35
            },
            "UFF": {
              "radius_of_gyration_A": 2.82,
              "PMI_amu_A2": [
                545,
                1105,
                1585
              ],
              "inertial_shape_factor": 0.65,
              "sphericity": 0.51,
              "eccentricity": 0.78,
              "asphericity": 0.36
            },
            "relative_differences_percent": {
              "radius_of_gyration": 1.44,
              "PMI_I1": 2.83,
              "PMI_I2": 2.31,
              "PMI_I3": 1.6,
              "inertial_shape_factor": 1.52,
              "sphericity": 1.92,
              "eccentricity": 1.3,
              "asphericity": 2.86,
              "all_key_metrics_below_10_percent": true
            }
          },
          "lipinski": {
            "logP": 2.3,
            "HBD": 1,
            "HBA": 5,
            "TPSA_A2": 68.3,
            "rotatable_bonds": 7,
            "passes_rule_of_five": true,
            "violations": 0
          },
          "images_and_files": {
            "2D_image_path": "./artifacts/pioglitazone_2d.png",
            "3D_MMFF_model_path": "./artifacts/pioglitazone_3d_MMFF.mol2",
            "3D_UFF_model_path": "./artifacts/pioglitazone_3d_UFF.mol2"
          },
          "consistency_summary": {
            "energy_difference_le_2_kcal_mol": true,
            "shape_metrics_relative_diff_lt_10_percent": true,
            "SAS_original_vs_normalized_agree": true,
            "lipinski_pass": true,
            "notes": "所有阈值均满足，无需额外解释。"
          }
        },
        "solution_outline": [
          "确认工具执行记录中的失败与通过项，说明将使用题干提供的独立计算数据进行验证。",
          "给出并重申规范化SMILES，与原始SMILES一致，进行SAS双通道交叉比对。",
          "报告SAS原始与规范化值，取最终SAS（保留1位小数），注明交叉验证一致。",
          "报告MMFF与UFF优化能量，计算能量差并核对是否≤2 kcal/mol。",
          "分别列出MMFF与UFF的3D形状描述符：回转半径、PMI三元组、惯性形状因子、球形度、离心率、非球形度；计算每个关键指标的相对差异百分比，核对是否<10%。",
          "报告Lipinski五规则的关键理化性质（logP、HBD、HBA、TPSA、可旋转键数），判定是否通过并给出违规数目。",
          "提供规范化SMILES与2D/3D文件路径，便于外部复核图像与3D结构。",
          "在一致性检验总结中逐项标注阈值是否满足，若不满足则需解释（本数据满足）。",
          "形成最终答案。"
        ],
        "verification": "核对步骤：1) 比较SAS_original_SMILES与SAS_normalized_SMILES，确认两者均为3.7且一致；2) 检查MMFF与UFF能量差：|112.5-111.2|=1.3≤2 kcal/mol，满足阈值；3) 逐项计算3D形状描述符相对差：例如Rg差=(2.82-2.78)/2.78×100%=1.44%，各PMI与形状指标相对差均<10%，满足要求；4) 检查Lipinski参数：logP=2.3<5，HBD=1≤5，HBA=5≤10，TPSA=68.3 Å^2适中，可旋转键数=7，违规数目=0，判定通过；5) 确认规范化SMILES与原始一致，并能在提供的路径找到2D/3D文件以复核结构。工具执行记录显示除chem_visualizer外均失败（ImportError），因此本题以题干提供的独立计算结果为准，验证结论如上。"
      }
    ],
    "refined_versions": [
      {
        "refined_question": "已知：目标分子为吡格列酮（Pioglitazone），SMILES：CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3。给定数据如下（按所示单位）：\n- 规范化SMILES（canonical）：CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3\n- 合成可及性分数（SAS）：原始SMILES：3.7；规范化SMILES：3.7\n- 力场优化能量：MMFF：112.5 kcal/mol；UFF：111.2 kcal/mol\n- 3D形状描述符：\n  • MMFF：回转半径 Rg：2.78 Å；主惯性矩 PMI（I1≤I2≤I3）：[530, 1080, 1560] amu·Å^2；惯性形状因子：0.66（无量纲）；球形度：0.52（无量纲）；离心率：0.77（无量纲）；非球形度：0.35（无量纲）\n  • UFF：回转半径 Rg：2.82 Å；主惯性矩 PMI（I1≤I2≤I3）：[545, 1105, 1585] amu·Å^2；惯性形状因子：0.65（无量纲）；球形度：0.51（无量纲）；离心率：0.78（无量纲）；非球形度：0.36（无量纲）\n- 成药性相关理化性质：logP：2.3；氢键供体 HBD：1；氢键受体 HBA：5；拓扑极性表面积 TPSA：68.3 Å^2；可旋转键数：7\n- 图像/文件路径：2D图像：./artifacts/pioglitazone_2d.png；3D模型（MMFF）：./artifacts/pioglitazone_3d_MMFF.mol2；3D模型（UFF）：./artifacts/pioglitazone_3d_UFF.mol2\n任务：\n(1) 报告最终SAS分数（保留1位小数），并说明原始与规范化SMILES的SAS是否一致。\n(2) 给出MMFF与UFF优化能量及其能量差ΔE（kcal/mol，保留1位小数），并验证是否满足ΔE≤2 kcal/mol。\n(3) 分别给出两套3D形状描述符（至少含Rg、PMI三分量、惯性形状因子、球形度、离心率、非球形度），并以MMFF为基准计算上述各项相对差异（% ，保留2位小数），验证是否均<10%。\n(4) 报告Lipinski五规则评估结果（是否通过、违规数目），并给出logP、HBD、HBA、TPSA、可旋转键数。\n(5) 提供规范化SMILES与2D/3D文件路径。\n(6) 汇总一致性检验结论；如有不满足阈值的项，需标注与解释。\n结果以数值形式给出：SAS保留1位小数；ΔE保留1位小数（kcal/mol）；相对差异保留2位小数（%）；其余量按所示单位原样报告。",
        "final_answer": {
          "(1) 最终SAS与一致性": {
            "SAS_final": "3.7（无量纲）",
            "SAS_original_SMILES": "3.7（无量纲）",
            "SAS_normalized_SMILES": "3.7（无量纲）",
            "cross_validated_consistent": true
          },
          "(2) 能量与差异": {
            "E_MMFF": "112.5 kcal/mol",
            "E_UFF": "111.2 kcal/mol",
            "ΔE": "1.3 kcal/mol",
            "verify_ΔE_le_2_kcal_per_mol": true
          },
          "(3) 3D形状描述符与相对差异": {
            "MMFF": {
              "Rg": "2.78 Å",
              "PMI": [
                "530 amu·Å^2",
                "1080 amu·Å^2",
                "1560 amu·Å^2"
              ],
              "inertial_shape_factor": "0.66（无量纲）",
              "sphericity": "0.52（无量纲）",
              "eccentricity": "0.77（无量纲）",
              "asphericity": "0.35（无量纲）"
            },
            "UFF": {
              "Rg": "2.82 Å",
              "PMI": [
                "545 amu·Å^2",
                "1105 amu·Å^2",
                "1585 amu·Å^2"
              ],
              "inertial_shape_factor": "0.65（无量纲）",
              "sphericity": "0.51（无量纲）",
              "eccentricity": "0.78（无量纲）",
              "asphericity": "0.36（无量纲）"
            },
            "relative_differences_%_vs_MMFF": {
              "Rg": "1.44%",
              "PMI_I1": "2.83%",
              "PMI_I2": "2.31%",
              "PMI_I3": "1.60%",
              "inertial_shape_factor": "1.52%",
              "sphericity": "1.92%",
              "eccentricity": "1.30%",
              "asphericity": "2.86%",
              "all_metrics_below_10%": true
            }
          },
          "(4) 成药性评估": {
            "passes_rule_of_five": true,
            "violations": 0,
            "logP": "2.3（无量纲）",
            "HBD": "1（个）",
            "HBA": "5（个）",
            "TPSA": "68.3 Å^2",
            "rotatable_bonds": "7（个）"
          },
          "(5) 结构与文件路径": {
            "normalized_SMILES": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3",
            "image_2D_path": "./artifacts/pioglitazone_2d.png",
            "model_3D_MMFF_path": "./artifacts/pioglitazone_3d_MMFF.mol2",
            "model_3D_UFF_path": "./artifacts/pioglitazone_3d_UFF.mol2"
          },
          "(6) 一致性汇总": {
            "SAS_original_vs_normalized_agree": true,
            "energy_difference_le_2_kcal_per_mol": true,
            "shape_metrics_relative_diff_lt_10_percent": true,
            "lipinski_pass": true,
            "notes": "所有阈值均满足，无需额外说明。"
          }
        }
      }
    ],
    "metadata_summary": {
      "subject": "Chemistry",
      "topic": "Analytical Chemistry",
      "original_question_id": "pioglitazone",
      "subject_topic_key": "Chemistry::Analytical Chemistry"
    }
  },
  "model": "glm-4.6v",
  "use_tools": true,
  "mode": "tool_mode",
  "rounds": 5,
  "messages": [
    {
      "role": "system",
      "content": "你是一个顶尖的 AI 科学助手，你的任务是解决来自物理、化学、生物等领域的复杂、多模态、多步骤问题。\n\n# 任务指令：两阶段方法\n\n你必须严格遵循以下两个阶段来回答问题：\n\n**阶段 1: 规划 (Planning)**\n在开始执行任何操作之前，你必须首先生成一个高阶的、分步骤的“计划”。这个计划应该概述你打算如何分解问题、使用哪些工具、以及工具之间的依赖关系。\n\n**阶段 2: 执行 (Execution)**\n在提交计划后，你将开始逐一执行。你必须严格遵循以下的 \"ReAct\" 格式 (Thought, Action, Observation)，直到你得出最终答案。\n\n---\n\n**输出格式规范**\n\n**[阶段 1: 规划]**\nPlan:\n\n1. [你的计划步骤 1，例如：分析输入图像中的分子结构]\n2. [你的计划步骤 2，例如：使用 `analyze_molecule` 工具获取 SMILES]\n3. [你的计划步骤 3，例如：将 SMILES 传入 `calculate_properties` 工具]\n4. ...\n5. [你的计划步骤 N，例如：总结所有属性并回答问题]\n\n**[阶段 2: 执行]**\nThought: [描述你当前的思考，你正处于计划的第几步，以及你为什么需要调用这个特定的工具。]\nAction: 请你在这一步发出工具调用\n\n[在你提交 Action 后，你将收到一个 Observation]\n\nObservation: [这里将由评测系统插入工具的返回结果]\n\n[然后你重复这个循环]\n\nThought: [基于上一步的 Observation，你的新思考。]\nAction: 请你在这一步发出工具调用\n\n...\n[当你收集到所有信息并准备好回答时]\n\nThought: [我已收集到所有必要信息，现在可以生成最终答案了。]\nFinal Answer: [这里是对原始问题的最终、完整回答。]"
    },
    {
      "role": "user",
      "content": "Calculate the Synthetic Accessibility Score (SAS) for Pioglitazone (吡格列酮), a third-generation thiazolidinedione antidiabetic drug. This PPARγ agonist enhances insulin sensitivity and is marketed under the trade name Actos. SMILES: CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3. Analyze its physicochemical properties, perform 3D structure optimization using MMFF force field, calculate 3D shape descriptors, and evaluate drug-likeness via Lipinski's Rule of Five. Report the final SAS score (rounded to 1 decimal place)."
    },
    {
      "role": "assistant",
      "content": "\n[阶段 1: 规划]\nPlan:\n\n1. 使用calculate_synthetic_accessibility工具计算吡格列酮的合成可及性分数（SAS）\n2. 使用mol_basic_physicochemical_info工具分析吡格列酮的理化性质和Lipinski五规则评估\n3. 使用optimize_geometry工具进行3D结构优化（使用MMFF力场）\n4. 使用get_3d_properties工具计算3D形状描述符\n5. 总结所有结果并报告最终的SAS分数（保留1位小数）\n",
      "tool_calls": [
        {
          "id": "call_-7982480150828054638",
          "type": "function",
          "function": {
            "name": "calculate_synthetic_accessibility",
            "arguments": "{\"smiles\": \"CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3\"}"
          }
        }
      ]
    },
    {
      "role": "tool",
      "content": {
        "result": 2.7
      },
      "tool_call_id": "call_-7982480150828054638"
    },
    {
      "role": "assistant",
      "content": "\nThought: 我已经获得了吡格列酮的SAS分数为2.7。现在需要继续分析其理化性质和Lipinski五规则评估，使用mol_basic_physicochemical_info工具。\nAction: mol_basic_physicochemical_info\n<arg_key>smiles</arg_key>\n<arg_value>CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3</arg_value>\n</tool_call>"
    },
    {
      "role": "tool",
      "content": {
        "result": "\n【基本信息】  SMILES                    CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3  Molecular Formula         C22H23NO5S  Molecular Weight          413.13  Heavy Atom Count          29  Total Atom Count          29\n【物化性质】  LogP                      2.37  TPSA                      89.54  H-Bond Donors             1  H-Bond Acceptors          5  Rotatable Bonds           8  Aromatic Rings            2  Total Rings               3\n【Lipinski规则】  违规数: 0  类药性: ✓ 是    ✓ MW ≤ 500    ✓ LogP ≤ 5    ✓ HBD ≤ 5    ✓ HBA ≤ 10",
        "info": "\n【基本信息】  SMILES                    CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3  Molecular Formula         C22H23NO5S  Molecular Weight          413.13  Heavy Atom Count          29  Total Atom Count          29\n【物化性质】  LogP                      2.37  TPSA                      89.54  H-Bond Donors             1  H-Bond Acceptors          5  Rotatable Bonds           8  Aromatic Rings            2  Total Rings               3\n【Lipinski规则】  违规数: 0  类药性: ✓ 是    ✓ MW ≤ 500    ✓ LogP ≤ 5    ✓ HBD ≤ 5    ✓ HBA ≤ 10"
      },
      "tool_call_id": "call_7a05b4bbc1f3433b"
    },
    {
      "role": "assistant",
      "content": "\nThought: 我已经获得了吡格列酮的理化性质和Lipinski五规则评估结果。现在需要进行3D结构优化，使用optimize_geometry工具，采用MMFF力场进行能量最小化。\nAction: optimize_geometry\n<arg_key>smiles</arg_key>\n<arg_value>CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3</arg_value>\n<arg_key>method</arg_key>\n<arg_value>ETKDGv3</arg_value>\n<arg_key>force_field</arg_key>\n<arg_value>MMFF</arg_value>\n<arg_key>max_iters</arg_key>\n<arg_value>200</arg_value>\n</tool_call>"
    },
    {
      "role": "tool",
      "content": {
        "result": 146.691814605027
      },
      "tool_call_id": "call_74d2fe0b857f403f"
    },
    {
      "role": "assistant",
      "content": "\nThought: 我已经完成了3D结构优化，现在需要计算3D形状描述符。使用get_3d_properties工具，采用ETKDGv3方法，conf_id设为0。\nAction: get_3d_properties\n<arg_key>smiles</arg_key>\n<arg_value>CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3</arg_value>\n<arg_key>method</arg_key>\n<arg_value>ETKDGv3</arg_value>\n<arg_key>conf_id</arg_key>\n<arg_value>0</arg_value>\n</tool_call>"
    },
    {
      "role": "tool",
      "content": {
        "pmi": [
          1571.083160136862,
          13235.786527332402,
          13960.643509888136
        ],
        "npr": [
          0.11253658608387823,
          0.9480785407891601
        ],
        "shape": "极端棒状/纤维状",
        "radius": 5.897949252701151,
        "asphericity": 0.7010693780647519,
        "eccentricity": 0.9936475817877211
      },
      "tool_call_id": "call_567190eb2f734879"
    },
    {
      "role": "assistant",
      "content": "\nThought: 我已收集到所有必要信息，现在可以生成最终答案。\nFinal Answer: \n\n## 吡格列酮（Pioglitazone）的全面分析报告\n\n### 1. 合成可及性分数（SAS）\n**SAS分数：2.7**（保留1位小数）\n\n### 2. 基本理化性质\n- **分子式**：C22H23NO5S\n- **分子量**：413.13\n- **LogP**：2.37\n- **拓扑极性表面积（TPSA）**：89.54 Å²\n- **氢键供体**：1\n- **氢键受体**：5\n- **可旋转键**：8\n- **芳香环**：2\n- **总环数**：3\n\n### 3. 类药性评估（Lipinski五规则）\n- **违规数**：0\n- **类药性**：✓ 是\n- **符合所有Lipinski规则**：\n  - ✓ 分子量 ≤ 500\n  - ✓ LogP ≤ 5\n  - ✓ 氢键供体 ≤ 5\n  - ✓ 氢键受体 ≤ 10\n\n### 4. 3D结构优化（MMFF力场）\n- **优化方法**：ETKDGv3\n- **能量最小化完成**：成功\n\n### 5. 3D形状描述符\n- **形状**：极端棒状/纤维状\n- **半径**：5.90 Å\n- **非球性**：0.70\n- **离心率**：0.99\n\n### 结论\n吡格列酮作为第三代噻唑烷二酮类抗糖尿病药物，表现出优异的类药性特征，完全符合Lipinski五规则。其SAS分数为2.7，表明该分子具有较好的合成可及性。3D结构分析显示分子呈极端棒状形态，这种线性结构可能与其作为PPARγ激动剂的功能有关。"
    },
    {
      "role": "user",
      "content": "现在请仅输出严格 JSON，必须完全匹配以下结构（键名、层级、字段齐全），所有数值用数字表示（保留2-3位小数），布尔用 true/false，字符串填写说明文字。不要输出任何解释文字或前后缀，也不要多余字段；若无法计算某值请给出可解析的近似值。\n\n{\n  \"call\": \"[字符串]\",\n  \"inputs\": {\n    \"smiles\": \"[字符串]\"\n  },\n  \"output\": {\n    \"SAS\": \"[数值]\",\n    \"interpretation\": \"[字符串]\",\n    \"difficulty_rating\": \"[字符串]\",\n    \"synthesis_feasibility\": \"[字符串]\",\n    \"complexity_factors\": \"[4个字符串的数组]\"\n  }\n}"
    },
    {
      "role": "assistant",
      "content": "\n{\n  \"call\": \"calculate_synthetic_accessibility\",\n  \"inputs\": {\n    \"smiles\": \"CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3\"\n  },\n  \"output\": {\n    \"SAS\": 2.70,\n    \"interpretation\": \"容易合成\",\n    \"difficulty_rating\": \"low\",\n    \"synthesis_feasibility\": \"high\",\n    \"complexity_factors\": [\n      \"分子量适中(413.13)\",\n      \"LogP值合理(2.37)\",\n      \"氢键供体/受体数量平衡\",\n      \"可旋转键数量适中(8)\"\n    ]\n  }\n}"
    }
  ],
  "metadata": {
    "subject": "Chemistry",
    "topic": "Analytical Chemistry",
    "image_path": [],
    "solution_steps": [
      "【分子识别与解析】解析Pioglitazone的SMILES字符串：CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3",
      "识别结构特征：噻唑烷二酮核心结构 + 双苯基侧链 + 柔性醚键连接",
      "【SAS计算】调用 calculate_synthetic_accessibility(smiles) 使用Ertl-Schuffenhauer算法",
      "基于分子复杂度、环系统（3个环：2个苯环+1个噻唑烷二酮环）、立体化学和合成片段库进行评估",
      "获得SAS = 2.7，处于\"相对容易合成\"范围（2.0-4.0）",
      "该分数反映了噻唑烷二酮类药物的典型合成可及性，适合商业化开发",
      "【理化性质分析】调用 mol_basic_physicochemical_info(smiles) 获取完整分子信息",
      "分子式：C22H23NO5S，分子量：413.13 g/mol（中等分子量药物）",
      "LogP = 2.37（良好的脂水平衡，有利于口服吸收）",
      "TPSA = 89.54 Ų（<140 Ų，有利于穿透生物膜）",
      "氢键供体：1（酰胺NH），氢键受体：5（羰基O + 磺酰O + 醚O）",
      "可旋转键：8（柔性侧链，有利于与受体结合）",
      "芳香环：2（双苯基结构），总环数：3（含噻唑烷二酮环）",
      "【Lipinski成药性评估】检查Lipinski五规则的四个标准",
      "✓ MW(413.13) ≤ 500 - 符合",
      "✓ LogP(2.37) ≤ 5 - 符合",
      "✓ HBD(1) ≤ 5 - 符合",
      "✓ HBA(5) ≤ 10 - 符合",
      "违规数 = 0，类药性 = ✓ 是（完全符合成药标准）",
      "【3D可视化】调用 chem_visualizer 生成多种视图",
      "生成Pioglitazone_2d.png：2D平面结构图，展示双苯基-醚-噻唑烷二酮骨架",
      "生成Pioglitazone_3d_projection.png：3D投影图，展示空间构象",
      "生成Pioglitazone_3d_matplotlib.png：3D立体图，展示柔性侧链的伸展构象",
      "【3D结构优化】调用 optimize_geometry(smiles, method='ETKDGv3', force_field='MMFF', max_iters=200)",
      "使用ETKDGv3算法生成初始3D坐标（改进的距离几何方法）",
      "初始能量：209.15 kcal/mol（未优化状态）",
      "MMFF力场优化后：146.69 kcal/mol",
      "能量降低：ΔE = -62.46 kcal/mol（显著的结构弛豫）",
      "优化消除了构象张力，得到能量最低的稳定构象",
      "【3D性质计算】调用 get_3d_properties(smiles, method='ETKDGv3', conf_id=0)",
      "主惯性矩：PMI1=1571.08, PMI2=13235.79, PMI3=13960.64 amu·Ų",
      "归一化惯性矩比：NPR1=0.113（PMI1/PMI3），NPR2=0.948（PMI2/PMI3）",
      "分子形状分类：极端棒状/纤维状（NPR1 < 0.5 且 NPR2 > 0.95）",
      "这种拉伸构象有利于插入PPARγ受体的结合口袋",
      "回转半径：Rg = 5.898 Å（分子质量分布的特征尺度）",
      "非球形度：asphericity = 0.701（高度偏离球形，0=球形，1=完全非球形）",
      "偏心率：eccentricity = 0.994（接近1，表示极度拉伸的椭球形）",
      "【结构-活性关系分析】双苯基侧链提供疏水相互作用",
      "噻唑烷二酮环是PPARγ激动的关键药效团",
      "柔性醚键允许构象适应性结合",
      "【合成难度评估】SAS=2.7对应\"相对容易合成\"（★★☆☆☆）",
      "合成路线：商品化起始原料 + 常规有机反应（醚化、酰化、环化）",
      "无复杂手性中心，合成步骤可控，适合大规模生产",
      "【药物开发价值】成药性优异（Lipinski零违规）+ 合成可及（SAS低）",
      "相比第一代曲格列酮（肝毒性）和第二代罗格列酮（心血管风险），吡格列酮安全性更好",
      "【最终答案】合成可及性分数 SAS = 2.7"
    ],
    "tool_expected": [
      "calculate_synthetic_accessibility",
      "mol_basic_physicochemical_info",
      "chem_visualizer",
      "optimize_geometry",
      "get_3d_properties"
    ],
    "golden_answer": [
      {
        "call": "calculate_synthetic_accessibility",
        "inputs": {
          "smiles": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3"
        },
        "output": {
          "SAS": 2.7,
          "interpretation": "相对容易合成（2.0-4.0范围）",
          "difficulty_rating": "★★☆☆☆",
          "synthesis_feasibility": "适合商业化生产，常规有机合成路线",
          "complexity_factors": [
            "3个环系统（2个苯环 + 1个噻唑烷二酮环）",
            "8个可旋转键（中等柔性）",
            "无手性中心（简化合成）",
            "标准官能团（醚、酰胺、磺酰）"
          ]
        }
      },
      {
        "call": "mol_basic_physicochemical_info",
        "inputs": {
          "smiles": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3"
        },
        "output": {
          "basic_info": {
            "SMILES": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3",
            "Molecular_Formula": "C22H23NO5S",
            "Molecular_Weight": 413.13,
            "Heavy_Atom_Count": 29,
            "Total_Atom_Count": 29
          },
          "physicochemical_properties": {
            "LogP": 2.37,
            "TPSA": 89.54,
            "H_Bond_Donors": 1,
            "H_Bond_Acceptors": 5,
            "Rotatable_Bonds": 8,
            "Aromatic_Rings": 2,
            "Total_Rings": 3
          },
          "lipinski_rule": {
            "violations": 0,
            "drug_like": true,
            "details": {
              "MW_check": "✓ 413.13 ≤ 500",
              "LogP_check": "✓ 2.37 ≤ 5",
              "HBD_check": "✓ 1 ≤ 5",
              "HBA_check": "✓ 5 ≤ 10"
            }
          },
          "oral_bioavailability_prediction": "优秀（LogP适中，TPSA<140，Lipinski零违规）"
        }
      },
      {
        "call": "chem_visualizer",
        "inputs": {
          "molecules": {
            "Pioglitazone": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3"
          }
        },
        "output": {
          "images_generated": [
            "./images/Pioglitazone_2d.png",
            "./images/Pioglitazone_3d_projection.png",
            "./images/Pioglitazone_3d_matplotlib.png"
          ],
          "structure_features_visualized": [
            "双苯基侧链（疏水区域）",
            "醚键连接（柔性铰链）",
            "酰胺键（氢键供体）",
            "噻唑烷二酮环（药效团）",
            "磺酰基（极性基团）"
          ]
        }
      },
      {
        "call": "optimize_geometry",
        "inputs": {
          "smiles": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3",
          "method": "ETKDGv3",
          "force_field": "MMFF",
          "max_iters": 200
        },
        "output": {
          "initial_energy": 209.15,
          "optimized_energy": 146.69,
          "energy_change": -62.46,
          "units": "kcal/mol",
          "conformer_0": "优化完成：209.15 → 146.69 kcal/mol (Δ=-62.46)",
          "optimization_details": {
            "force_field": "MMFF94（Merck分子力场）",
            "convergence": "成功收敛至能量最小值",
            "structural_relaxation": "消除初始构象的张力和重叠"
          },
          "optimized_structure_features": [
            "双苯环趋于平面",
            "柔性侧链采用伸展构象",
            "噻唑烷二酮环保持刚性平面结构",
            "分子整体呈棒状构象"
          ]
        }
      },
      {
        "call": "get_3d_properties",
        "inputs": {
          "smiles": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3",
          "method": "ETKDGv3",
          "conf_id": 0
        },
        "output": {
          "principal_moments_of_inertia": {
            "PMI1": 1571.08,
            "PMI2": 13235.79,
            "PMI3": 13960.64,
            "units": "amu·Ų",
            "physical_meaning": "PMI1 << PMI2 ≈ PMI3 表明棒状分子"
          },
          "normalized_PMI_ratios": {
            "NPR1": 0.113,
            "NPR2": 0.948,
            "shape_space_position": "接近棒状极限（rod limit）"
          },
          "shape_classification": "极端棒状/纤维状",
          "shape_criteria": "NPR1 < 0.5 且 NPR2 > 0.95",
          "shape_implications": "有利于插入PPARγ配体结合域（Y形口袋）",
          "radius_of_gyration": {
            "Rg": 5.898,
            "units": "Å",
            "interpretation": "分子尺寸较大，典型的中等分子量药物"
          },
          "asphericity": {
            "value": 0.701,
            "interpretation": "高度非球形（0=球形，1=完全非球形）",
            "structural_basis": "拉伸的双苯基-醚-噻唑烷二酮骨架"
          },
          "eccentricity": {
            "value": 0.994,
            "interpretation": "接近1，表示极度拉伸的椭球形分子",
            "aspect_ratio": "长轴远大于短轴（高纵横比）"
          }
        }
      },
      {
        "final_answer": {
          "SAS": 2.7,
          "molecule_name": "Pioglitazone (吡格列酮)",
          "trade_name": "Actos (艾汀)",
          "chemical_class": "噻唑烷二酮类（Thiazolidinedione, TZD）",
          "generation": "第三代TZD药物",
          "synthesis_difficulty": "相对容易合成（★★☆☆☆）",
          "drug_likeness": "类药性优异（Lipinski零违规）",
          "therapeutic_use": "2型糖尿病治疗",
          "mechanism_of_action": "PPARγ激动剂，增强胰岛素敏感性",
          "approval_year": 1999,
          "safety_profile": "相比罗格列酮，心血管安全性更好",
          "pharmacokinetics": {
            "oral_bioavailability": "良好（LogP=2.37有利于吸收）",
            "protein_binding": "高（>99%）",
            "half_life": "3-7小时（活性代谢物更长）"
          }
        }
      }
    ],
    "original_question_id": "pioglitazone"
  },
  "metadata_summary": {
    "subject": "Chemistry",
    "topic": "Analytical Chemistry",
    "original_question_id": "pioglitazone",
    "subject_topic_key": "Chemistry::Analytical Chemistry"
  },
  "answer_template": {
    "call": "[字符串]",
    "inputs": {
      "smiles": "[字符串]"
    },
    "output": {
      "SAS": "[数值]",
      "interpretation": "[字符串]",
      "difficulty_rating": "[字符串]",
      "synthesis_feasibility": "[字符串]",
      "complexity_factors": "[4个字符串的数组]"
    }
  },
  "golden_standard": {
    "call": "calculate_synthetic_accessibility",
    "inputs": {
      "smiles": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3"
    },
    "output": {
      "SAS": 2.7,
      "interpretation": "相对容易合成（2.0-4.0范围）",
      "difficulty_rating": "★★☆☆☆",
      "synthesis_feasibility": "适合商业化生产，常规有机合成路线",
      "complexity_factors": [
        "3个环系统（2个苯环 + 1个噻唑烷二酮环）",
        "8个可旋转键（中等柔性）",
        "无手性中心（简化合成）",
        "标准官能团（醚、酰胺、磺酰）"
      ]
    }
  },
  "expected_format": "structured_json",
  "model_structured_answer": {
    "call": "calculate_synthetic_accessibility",
    "inputs": {
      "smiles": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3"
    },
    "output": {
      "SAS": 2.7,
      "interpretation": "容易合成",
      "difficulty_rating": "low",
      "synthesis_feasibility": "high",
      "complexity_factors": [
        "分子量适中(413.13)",
        "LogP值合理(2.37)",
        "氢键供体/受体数量平衡",
        "可旋转键数量适中(8)"
      ]
    }
  },
  "answer_extraction_success": true,
  "model_raw_answer": "\n{\n  \"call\": \"calculate_synthetic_accessibility\",\n  \"inputs\": {\n    \"smiles\": \"CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3\"\n  },\n  \"output\": {\n    \"SAS\": 2.70,\n    \"interpretation\": \"容易合成\",\n    \"difficulty_rating\": \"low\",\n    \"synthesis_feasibility\": \"high\",\n    \"complexity_factors\": [\n      \"分子量适中(413.13)\",\n      \"LogP值合理(2.37)\",\n      \"氢键供体/受体数量平衡\",\n      \"可旋转键数量适中(8)\"\n    ]\n  }\n}",
  "model_last_assistant_message": {
    "role": "assistant",
    "content": "\n{\n  \"call\": \"calculate_synthetic_accessibility\",\n  \"inputs\": {\n    \"smiles\": \"CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3\"\n  },\n  \"output\": {\n    \"SAS\": 2.70,\n    \"interpretation\": \"容易合成\",\n    \"difficulty_rating\": \"low\",\n    \"synthesis_feasibility\": \"high\",\n    \"complexity_factors\": [\n      \"分子量适中(413.13)\",\n      \"LogP值合理(2.37)\",\n      \"氢键供体/受体数量平衡\",\n      \"可旋转键数量适中(8)\"\n    ]\n  }\n}"
  },
  "evaluation_score": 0.5,
  "evaluation_summary": "匹配字段: 5/10 (得分: 50.00%)",
  "evaluation_details": {
    "call": {
      "path": "call",
      "expected": "calculate_synthetic_accessibility",
      "actual": "calculate_synthetic_accessibility",
      "status": "match",
      "match_type": "exact"
    },
    "inputs.smiles": {
      "path": "inputs.smiles",
      "expected": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3",
      "actual": "CCc1ccc(cc1)CCOc2ccc(cc2)CC(=O)NC3=CC(=O)S(=O)(=O)C3",
      "status": "match",
      "match_type": "exact"
    },
    "output.SAS": {
      "path": "output.SAS",
      "expected": 2.7,
      "actual": 2.7,
      "expected_num": 2.7,
      "actual_num": 2.7,
      "status": "match",
      "match_type": "exact"
    },
    "output.interpretation": {
      "path": "output.interpretation",
      "expected": "相对容易合成（2.0-4.0范围）",
      "actual": "容易合成",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "output.difficulty_rating": {
      "path": "output.difficulty_rating",
      "expected": "★★☆☆☆",
      "actual": "low",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "output.synthesis_feasibility": {
      "path": "output.synthesis_feasibility",
      "expected": "适合商业化生产，常规有机合成路线",
      "actual": "high",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "output.complexity_factors[0]": {
      "path": "output.complexity_factors[0]",
      "expected": "3个环系统（2个苯环 + 1个噻唑烷二酮环）",
      "actual": "分子量适中(413.13)",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "output.complexity_factors[1]": {
      "path": "output.complexity_factors[1]",
      "expected": "8个可旋转键（中等柔性）",
      "actual": "LogP值合理(2.37)",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "output.complexity_factors[2]": {
      "path": "output.complexity_factors[2]",
      "expected": "无手性中心（简化合成）",
      "actual": "氢键供体/受体数量平衡",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "output.complexity_factors[3]": {
      "path": "output.complexity_factors[3]",
      "expected": "标准官能团（醚、酰胺、磺酰）",
      "actual": "可旋转键数量适中(8)",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    }
  },
  "mode_folder": "with_tools_react"
}